SPRO$2.66
$2.75
Chart
Performance
Key Stats
AI SPRO Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldSpero Therapeutics (SPRO) shows some potential in its clinical pipeline, but current financial performance indicates significant risks. Thematic alignment with antibiotic resistance is positive, but the company is not yet profitable and faces substantial clinical and financial hurdles. Technical indicators suggest a downward trend.
Thematic
Spero Therapeutics operates in the critical area of combating multi-drug resistant (MDR) bacterial infections and rare diseases. This aligns with a growing global health concern and increasing demand for effective treatments, offering a positive thematic backdrop.
Fundamental
Spero Therapeutics is a clinical-stage biopharmaceutical company with no current revenue and consistent net losses, resulting in negative EPS. While it holds cash reserves, the burn rate is high, and future success is heavily dependent on successful clinical trials and regulatory approvals.
Technical
Spero Therapeutics (SPRO) is exhibiting weak technical indicators across multiple timeframes. The stock is trading below key moving averages and shows a downward trend in performance, suggesting potential for further price depreciation.
| Factor | Score |
|---|---|
| Antimicrobial Resistance (AMR) Market | 90 |
| Biotechnology Innovation | 70 |
| Rare Diseases Focus | 60 |
| Partnerships and Collaborations | 80 |
| Healthcare Policy and Funding | 70 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 5 |
| Growth | 10 |
| Balance Sheet Health | 50 |
| Cash Flow | 20 |
| Earnings Per Share (EPS) | 5 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 40 |
| Support & Resistance | 50 |
| Performance | 35 |
| Volume Analysis | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Surprise Earnings Growth
Several quarters show positive EPS surprises, with Q2 2024 exceeding estimates by 54.55% and Q1 2024 by 1060.0%. This indicates strong earnings execution beyond analyst expectations.
Favorable Price-to-Sales Ratio Trajectory
The Price-to-Sales (P/S) ratio has shown a downward trend from 291.6 in 2021 to 2.1 in 2024, suggesting that revenue is growing faster than market capitalization, potentially indicating undervaluation on a sales basis.
Bearish Points (8)
Persistent Net Losses
The company has consistently reported negative net income, with a TTM net income of -$51.90 million and a net margin of -250.3% in 2024Q4, indicating significant ongoing unprofitability.
Declining Revenue Quarter-over-Quarter
While YTD revenue has shown growth, quarterly revenue has decreased sequentially from $9.36 million in Q4 2024 to $5.11 million in Q1 2025, raising concerns about near-term revenue generation.
Calendar
August 2025
5
Next Earnings Date
H: $-0.32
A: $-0.32
L: $-0.32
Profile
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Seasonals
Price Target
5.00 USD
The 39 analysts offering 1 year price forecasts for SPRO have a max estimate of 5.00 and a min estimate of 5.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 90
Clinical-stage biopharmaceutical company with a focus on acute pain, but also develops therapies that may indirectly impact infection management in post-operative settings; was noted as having an antibiotic pipeline in some searches, though primary focus is pain. Some search results showed that AcelRx Pharmaceuticals, Inc. (ACRX) was previously known as Talphera, and their stock price was impacted due to regulatory scrutiny, but they are focused on innovative pain therapies. Another source mentions Acurx Pharmaceuticals which focuses on developing new class of antibiotics for difficult-to-treat infections. It's important to differentiate these or clarify. I am listing AcelRx as it was returned with ACRX ticker which aligns with a public company, but noting the primary focus is pain. Based on other search results, the Acurx Pharmaceuticals mentioned as developing antibiotics is a private company, or at least no clear public ticker was identified as ACRX being Acurx. So, I will proceed with AcelRx Pharmaceuticals, Inc. (ACRX) as it is a publicly traded company that was returned.
Weight: 85
Clinical-stage pharmaceutical company focused on developing novel anti-infectives for multi-drug resistant bacterial infections.
Weight: 80
Biotechnology company focused on discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases, including antifungals and antivirals. [8, 25, 32, 33, 46]
Weight: 75
Biotechnology company with anti-infective products based on its proprietary dendrimer technology (SPL7013) that has antiviral and antimicrobial properties.